- May 6, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Banzel
Synonyms :
rufinamide
Class :
Anticonvulsants, Other
Dosage Forms & Strengths
Tablet
200mg
400mg
Oral suspension
40mg/ml
400-800 mg orally each day divided twice daily
Maintenance dose- increase the daily dose by 400-800 mg each day unless the 3200 mg dose for each day is acquired
It is not known if the drug is effective at the lowest dose
Dose Modification
In the case of renal impairment or hemodialysis, adjust the dose
Dosage Forms & Strengths
Tablet
200mg
400mg
Oral suspension
40mg/ml
For more than 1 year-
10 mg/kg each day orally divided twice daily
Maintenance dose- increase the dose by 10 mg/kg every alternate day
Give a maximum of 45 mg/kg each day divided twice daily
Do not exceed the dose of more than 3200 mg/day
It is not known if the drug is effective at the lowest dose
Dose Modification
In the case of renal impairment or hemodialysis, adjust the dose
may decrease the diagnostic effect when combined with metyrapone
may have an increased arrhythmogenic effect when combined with lamotrigine
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
it increases the toxicity of CNS depressants
it increases the toxicity of CNS depressants
it increases the toxicity of CNS depressants
it increases the toxicity of CNS depressants
it increases the toxicity of CNS depressants
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
when both drugs are combined, there may be an increased metabolism of etoposide
when both drugs are combined, there may be an increased metabolism of vinblastine
antiseizure agents may diminish the diagnostic effect of metyrapone
mefloquine may diminish the therapeutic effect of antiseizure agents
it increases the toxicity of CNS depressants
it increases the toxicity of CNS depressants
it decreases the efficacy of antiseizure agents
it decreases the concentration of antiseizure agents in the serum
may increase the toxic effect of CNS depressants
- may increase the toxic effect of antipsychotic agents
may increase the CNS depressant effect of CNS depressants
may increase the toxic effect of CNS depressants
may increase the toxic effect of antipsychotics
may increase the toxic effect of Antipsychotic Agents
may increase the toxic effect of Seizure Threshold, Lowering Potential agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of iomeprol
valproate products increase the concentration of rufinamide in serum
they increase the toxicity of iobitridol
seizure lowering agents increase the toxic or adverse effects of iopamidol
seizure lowering agents increase the toxic or adverse effects of iohexol
Actions and Spectrum:
Actions:
rufinamide is an antiepileptic drug primarily used to treat seizures associated with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy. It works by modulating the activity of sodium channels in the brain, which helps to reduce the abnormal electrical activity that leads to seizures.
Spectrum:
rufinamide is primarily indicated for treating seizures associated with Lennox-Gastaut syndrome (LGS) in adults and children aged 1 year and older. LGS is a severe form of epilepsy characterized by multiple seizure types, including tonic (stiffening), atonic (loss of muscle tone), atypical absence (brief loss of awareness), and myoclonic (sudden, brief muscle jerks) seizures. rufinamide has been shown to reduce the frequency of these seizures in LGS patients.
Frequency not defined
Diplopia
Fatigue
Dizziness
Somnolence
Vomiting
Nausea
Headache
Black Box Warning:
None
Contraindication/Caution:
Contraindications